HROW Stock Analysis
HR
Uncovered
Harrow Health Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Harrow Health, Inc. engages in the development, production, and sale of innovative medications. The company is headquartered in Nashville, Tennessee and currently employs 182 full-time employees. The company went IPO on 2013-02-08. The firm serves ophthalmologists and optometrists by providing branded ophthalmic pharmaceuticals and compounded prescription medicines. The firm's business specializes in the development, production and sale of medications that serve unmet needs in the marketplace through its subsidiaries and deconsolidated companies. Its five branded ophthalmic products include ILEVRO, NEVANAC, VIGAMOX, MAXIDEX, and TRIESENCE. The firm owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical business, and Visionology, Inc. (Visionology), a direct-to-consumer eye care subsidiary focused on chronic eye disease. In addition, the Company holds Surface Ophthalmics, Inc. (Surface) and Melt Pharmaceuticals, Inc. (Melt). The company also owns royalty rights in various drug candidates being developed by Surface and Melt.